Clinical trials: Diseases/Diagnoses
Cerebral Vasospasm
Non-Significant Risk Study Comparing the Nautilus NeuroWaveTM to Transcranial Doppler as an Aid to Diagnosing Vasospasm
The purpose of the study is to determine the sensitivity, specificity and predictive values of the Jan Medical NeuroWave System in detecting moderate and severe vasospasm in comparison to Trans Cranial Doppler(TCD).
- Trial name
- NCT01595802
- Testing
- Nautilus NeuroWave, Transcranial Doppler (TCD)
- Where
- United States
- Volunteers
- 92 people
- Sponsor
- Jan Medical, Inc.
Arrhythmias, Cardiac
Automated Diagnostic Performance of Smartwatch ECG for Arrhythmia Detection Using the PulseAI Neural Network.
The study is to evaluate the performance of the PulseAI neural network technology at interpreting ECG data recorded using a single-lead Smartwatch (Apple Watch).
- Trial name
- NCT05668377
- Testing
- PulseAI ECG Platform
- Where
- Ireland
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- PulseAI Ltd
MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease, NAFLD - Non-Alcoholic Fatty Liver Disease
Development of a Quantifiable Ultrasound Biomarker for Hepatic Steatosis
The research study is considering a non-invasive way to measure the percentage of fat in the liver using ultrasound. This could help detect early signs of a very common condition called metabolic dysfunction-associated steatotic…
- Trial name
- LYNX (NCT07270601)
- Testing
- Verasonics NXT Data Acquisition System, Philips EPIQ Elite, EchoSense FibroScan
- Where
- United States
- Volunteers
- 110 people, healthy volunteers welcome
- Sponsor
- ContextVision AB
Diabetes Mellitus, Type 2
Insulin Resistance as Primary Pathogenesis in Newly Diagnosed, Drug naïve Type 2 Diabetes Patients in Korea
The purpose of this study is investigating the clinical characteristics of newly diagnosed, drug naïve type 2 diabetic patients according to insulin secretion and insulin resistance.
- Trial name
- SURPRISE (NCT01154244)
- Testing
- HOMA-IR
- Where
- 2 sites in South Korea
- Volunteers
- 1,439 people
- Sponsor
- GlaxoSmithKline
Diabetic Retinopathy, DR, Diabetic Mellitus
Efficacy and Safety of AEYE Diagnostic Screening (AEYE-DS) Software Device for Detection of Diabetic Retinopathy From Digital Funduscopic Images
The goal of this clinical trial is to learn about the performance of the AEYE-DS Software Device to automatically detect more than mild Diabetic Retinopathy (mtmDR) in adult participants diagnosed with Diabetic Mellitus (DM)…
- Trial name
- NCT06241664
- Testing
- AEYE-DS Software
- Where
- United States
- Volunteers
- 601 people
- Sponsor
- AEYE Health Inc
Brain and Central Nervous System Tumors
Prinomastat Plus Temozolomide Following Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
RATIONALE: Prinomastat may stop the growth of glioblastoma multiforme by stopping blood flow to the tumor. Drugs used in chemotherapy stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00004200
- Testing
- prinomastat, temozolomide
- Where
- United States
- Sponsor
- Pfizer
COPD
Portable Oxygen Concentrator to Improve Quality of Life in Chronic Obstructive Pulmonary Disease
Evaluate subjects in an prospective observational study Subjects will be administered scientifically validated questionnaires Determine the affect of the Portable Oxygen Concentrator (POC) on improvements in: 1.
- Trial name
- NCT01948544
- Where
- 3 sites in United States
- Volunteers
- 27 people
- Sponsor
- StratiHealth
Coronary Artery Disease
RADIQAL Study (Radiation Dose and Image Quality Trial)
The Azurion R4.0 is developed by Philips Medical Systems Nederland B.V., a Philips Healthcare company. The Azurion is an interventional X-ray system which is used for live X-ray imaging during invasive cardiac procedures.
- Trial name
- RADIQAL (NCT06944509)
- Testing
- treatment with the Azurion system with Xres5, Azurion with Clairy IQ
- Where
- 6 sites in United States, Czechia and 2 more
- Volunteers
- 824 people
- Sponsor
- Philips Clinical & Medical Affairs Global
Hepatocellular Carcinoma
Study of Tivantinib in Subjects With Inoperable Hepatocellular Carcinoma (HCC) Who Have Been Treated With One Prior Therapy
The purpose of this study is to determine if tivantinib (ARQ 197) is effective in treating patients with MET diagnostic-high hepatocellular carcinoma (liver cancer) who have already been treated once with another therapy.
- Trial name
- METIV-HCC (NCT01755767)
- Testing
- Tivantinib
- Where
- 112 sites in United States, Argentina and 14 more
- Volunteers
- 383 people
- Sponsor
- Daiichi Sankyo
Breast Cancer
Diagnostic Performance of Breast Cancer Screening Second Reading Process Assisted by AI
The goal of this clinical trial is to compare, for the second reading of screening mammograms, the standard of care with an AI assisted scenario.
- Trial name
- IMA-L2 (NCT05800132)
- Testing
- MammoScreen
- Where
- 7 sites in France
- Volunteers
- 5,000 people, healthy volunteers welcome
- Sponsor
- Therapixel
NASH/MASH, NAFLD/MASLD
A Study Evaluating Efruxifermin in Subjects With Non-invasively Diagnosed Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Nonalcoholic Fatty Liver Disease (NAFLD)/Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
The aim of this study is to assess the safety and tolerability of EFX compared to placebo in subjects with non-invasively diagnosed NASH/MASH and NAFLD/MASLD.
- Trial name
- NCT06161571
- Testing
- Efruxifermin
- Where
- 211 sites in United States, Argentina and 11 more
- Volunteers
- 700 people
- Sponsor
- Akero Therapeutics, Inc
Focal Onset Seizure
Open-label Study of Cenobamate Monotherapy in Adult Subjects With Newly Diagnosed or Recurrent Partial-Onset Epilepsy
Cenobamate (YKP3089) is a small molecule approved in the United States (US), Europe and several other countries around the world for the treatment of Partial-Onset (focal) seizures in adult subjects (≥18 years of age).
- Trial name
- NCT06453213
- Testing
- Cenobamate
- Where
- 19 sites in United States
- Volunteers
- 49 people
- Sponsor
- SK Life Science, Inc.
CML, Chronic Phase
A Study of the Efficacy and Safety of Flumatinib in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase.
It's a double-blind , randomized ,multi-center study. The purpose of this study is to explore the efficacy and safety of flumatinib 400mg once daily (QD) versus 600mg QD as the first line therapy in patients with chronic myleiod…
- Trial name
- NCT05353205
- Testing
- Flumatinib mesylate tablets (400mg), Flumatinib mesylate tablets (600mg)
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Jiangsu Hansoh Pharmaceutical Co., Ltd.
Congestive Heart Failure
Retrograde Delivery of BMAC (Bone Marrow Aspirate Concentrate) for Congestive Heart Failure
The primary objective of this feasibility study is to provide clinical data to demonstrate the safety and activity of a concentrate of nucleated cells from bone marrow aspirate (BMAC) produced with the Harvest Bone Marrow…
- Trial name
- NCT01299324
- Testing
- BMAC infusion
- Where
- 3 sites in Germany, India and 1 more
- Volunteers
- 30 people
- Sponsor
- Harvest Technologies
Pancreatic Cancer
A Single-Patient Study Using AGS 006
Argos Therapeutics, Inc., (Argos) proposes to study AGS-006 in a subject with newly diagnosed resectable pancreatic cancer. The AGS 006 immunotherapeutic may potentially offer a desired additional option to conventional…
- Trial name
- NCT00664482
- Testing
- AGS-006
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Argos Therapeutics
Myelodysplastic Syndromes
Tamibarotene Plus Azacitidine in Participants With Newly Diagnosed RARA-positive Higher-Risk Myelodysplastic Syndrome
This study compares the efficacy of Tamibarotene in combination with azacitidine to azacitidine in combination with placebo in participants who are Retinoic Acid Receptor Alpha (RARA) positive, and newly diagnosed with…
- Trial name
- NCT04797780
- Testing
- Tamibarotene, Azacitidine
- Where
- 128 sites in United States, Austria and 11 more
- Volunteers
- 246 people
- Sponsor
- Syros Pharmaceuticals
Alpha 1-Antitrypsin Deficiency
The Impact of Delayed Diagnosis of Alpha-1 Antitrypsin Deficiency
The objective of this study is to prospectively assess whether there is any interval between first symptom and initial diagnosis that is experienced by patients with newly diagnosed alpha-1 antitrypsin deficiency (AATD) and then…
- Trial name
- NCT03039335
- Where
- United States
- Volunteers
- 43 people
- Sponsor
- Biocerna LLC
Prostate Cancer
Prostate Guided Biopsy Study Evaluating the Diagnostic Performance of Prostate HistoScanning
The primary objective of the PHSTT-01 trial is to determine if prostate HistoScanning (HS) analysis can be used to improve the detection of clinically significant prostate cancer (PCa), and potentially reduce the burden and…
- Trial name
- PHSTT-01 (NCT01950871)
- Testing
- Prostate HistoScanning
- Where
- 34 sites in Austria, Belgium and 16 more
- Volunteers
- 80 people
- Sponsor
- Advanced Medical Diagnostics s.a.
Crohn Disease, Complex Perianal Fistula
A Study to Check How Often People Treated With Darvadstrocel for Crohn's Disease Are Diagnosed With Cancer
The main aim is to learn about the risk of cancer after treatment with darvadstrocel compared to other standards of care in people with Crohn's Disease (CD).
- Trial name
- NCT04971525
- Where
- 4 sites in France, Germany and 2 more
- Sponsor
- Takeda
Ovarian Cancer, Fallopian Tube Cancer
A Study of the Efficacy and Safety of Bevacizumab in Chinese Women With Newly Diagnosed, Previously Untreated Stage III or Stage IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
This multicenter, double-blind, 2-arm, randomized study will evaluate the efficacy and safety of bevacizumab plus paclitaxel and caboplatin compared with placebo plus paclitaxel and caboplatin in Chinese participants with newly…
- Conditions
- Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
- Trial name
- NCT03635489
- Testing
- Paclitaxel, Bevacizumab, Carboplatin
- Where
- 16 sites in China
- Volunteers
- 100 people
- Sponsor
- Hoffmann-La Roche
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.